ME: חוב כולל להון 23andMe Inc.

A strategic crisis and waning interest in DNA testing have stripped 23andMe Holding Co. (ME) of its pricing power, forcing the business to rely on data monetization through pharmaceutical partnerships and growth in paid subscribers. The company's price chart on the GURU.Markets platform shows that the separate_debt_total_eq metric stands at 0.97. Meanwhile, aggressive pressure from laboratories and dumping by new entrants create serious risks to stability.

This metric is calculated as the ratio of total liabilities to net equity, reflecting the extent to which the financing structure depends on external borrowings. An increase in this metric signals a decline in financial stability, which is critical for 23andMe Holding Co. (ME) given the support of energy-intensive sequencer and server infrastructure; therefore, the dynamics of the debt-to-equity ratio allow for an assessment of default risks and the risk of breaching loan covenants.